Abstract
Brain atrophy caused by neuronal loss is a prominent pathological feature of Alzheimers disease (AD). Amyloid (A ), the major component of senile plaques, is considered to play a central role in neuronal cell death. In addition to removal of the toxic Aβ , direct suppression of neuronal loss is an essential part of AD treatment; however, no such neuroprotective therapies have been developed. Excess amount of Aβ evokes multiple cytotoxic mechanisms, involving increase of the intracellular Ca2+ level, oxidative stress, and receptor-mediated activation of cell-death cascades. Such diversity in cytotoxic mechanisms induced by Aβ clearly indicates a complex nature of the AD-related neuronal cell death. We have identified a 24-residue peptide, Humanin (HN), which suppresses in vitro neuronal cell death caused by all AD-related insults, including Aβ , so far tested. The anti-AD effect of HN has been further confirmed in vivo using mice with Aβ -induced amnesia. Altogether, such potent neuroprotective activity of HN against AD-relevant cytotoxicity both in vitro and in vivo suggests the potential clinical applications of HN in novel AD therapies aimed at controlling neuronal death.
Keywords: Alzheimer's disease, neuronal death, amyloid, amyloid precursor protein (APP), presenilin (PS), Humanin (HN), neuroprotection
Current Neuropharmacology
Title: Neuronal Cell Death in Alzheimers Disease and a Neuroprotective Factor, Humanin
Volume: 4 Issue: 2
Author(s): Takako Niikura, Hirohisa Tajima and Yoshiko Kita
Affiliation:
Keywords: Alzheimer's disease, neuronal death, amyloid, amyloid precursor protein (APP), presenilin (PS), Humanin (HN), neuroprotection
Abstract: Brain atrophy caused by neuronal loss is a prominent pathological feature of Alzheimers disease (AD). Amyloid (A ), the major component of senile plaques, is considered to play a central role in neuronal cell death. In addition to removal of the toxic Aβ , direct suppression of neuronal loss is an essential part of AD treatment; however, no such neuroprotective therapies have been developed. Excess amount of Aβ evokes multiple cytotoxic mechanisms, involving increase of the intracellular Ca2+ level, oxidative stress, and receptor-mediated activation of cell-death cascades. Such diversity in cytotoxic mechanisms induced by Aβ clearly indicates a complex nature of the AD-related neuronal cell death. We have identified a 24-residue peptide, Humanin (HN), which suppresses in vitro neuronal cell death caused by all AD-related insults, including Aβ , so far tested. The anti-AD effect of HN has been further confirmed in vivo using mice with Aβ -induced amnesia. Altogether, such potent neuroprotective activity of HN against AD-relevant cytotoxicity both in vitro and in vivo suggests the potential clinical applications of HN in novel AD therapies aimed at controlling neuronal death.
Export Options
About this article
Cite this article as:
Niikura Takako, Tajima Hirohisa and Kita Yoshiko, Neuronal Cell Death in Alzheimers Disease and a Neuroprotective Factor, Humanin, Current Neuropharmacology 2006; 4 (2) . https://dx.doi.org/10.2174/157015906776359577
DOI https://dx.doi.org/10.2174/157015906776359577 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
A synopsis on the linkage between age-related dementias and vascular disorders
CNS & Neurological Disorders - Drug Targets Amyotrophic Lateral Sclerosis: From Research to Therapeutic Attempts and Therapeutic Perspectives
Current Medicinal Chemistry Chemical and Pharmacological Aspects of Heteroaryl-Nitrones
Current Medicinal Chemistry Locus (Coeruleus) Minoris Resistentiae in Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Novel Ferulic Acid-donepezil Hybrids as Multifunctional Agents for th e Treatment of Alzheimer’s Disease with Butyrylcholinesterase, Amyloid- β, Antioxidant and Neuroprotective Properties
Letters in Drug Design & Discovery Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Review of Vital Signs Monitoring Systems – Patient’s Acceptability, Issues and Challenges
Neuroscience and Biomedical Engineering (Discontinued) Neuropsychiatric Symptoms in Amnestic Mild Cognitive Impairment: Increased Risk and Faster Progression to Dementia
Current Alzheimer Research RNA Interference as a Tool for Alzheimers Disease Therapy
Mini-Reviews in Medicinal Chemistry Targeting of NMDA Receptors in the Treatment of Major Depression
Current Pharmaceutical Design MicroRNAs: Emerging Role in the Endogenous μ Opioid System
CNS & Neurological Disorders - Drug Targets Omega-3 Fatty Acids in the Management of Epilepsy
Current Topics in Medicinal Chemistry Synaptic Fatigue is More Pronounced in the APP/PS1 Transgenic Mouse Model of Alzheimers Disease
Current Alzheimer Research Health Service Utilization and Costs of Depressive Symptoms in Late Life - A Systematic Review
Current Pharmaceutical Design Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Diagnostic and Prognostic Potential of Retinal Biomarkers in Early On-Set Alzheimer’s Disease
Current Alzheimer Research Ontologies of Drug Discovery and Design for Neurology, Cardiology and Oncology
Current Pharmaceutical Design Variability in the Response to Non-pharmacological Treatments in Patients with Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine